Summarized by Masters of Longevity from Longevity Technology.
Alzheon launched ORION-E4, a Phase 3 trial testing ALZ-801 in early Alzheimer’s.
Key Takeaways
- Alzheon launched ORION-E4 to replicate prior subgroup benefits.
- The trial is testing oral valiltramiprosate (ALZ-801) in early Alzheimer’s.
- Subgroup findings are observational and their causality remains unproven.
